Showing papers by "Garth L. Nicolson published in 2014"
TL;DR: In updated versions of the model more emphasis has been placed on the mosaic nature of the macrostructure of cellular membranes where many protein and lipid components are limited in their rotational and lateral motilities in the membrane plane, especially in their natural states.
546 citations
TL;DR: Recent clinical trials have shown the benefits of Lipid Replacement Therapy in restoring mitochondrial function and reducing fatigue in aged subjects and patients with a variety of clinical diagnoses that are characterized by loss of mitochondria function and include fatigue as a major symptom.
94 citations
TL;DR: This special issue of BBA Biomembranes aims to reflect the current status of this field, placing particular attention on the most recent advances in membrane structure, composition and dynamics, especially membrane lipids, as well as their modifications by therapeutic intervention.
26 citations
TL;DR: The expression levels of MTA1 correlate well with the malignant properties of human cancers, strongly suggesting that MTA1 and possibly other MTA proteins (and their genes) could be a new class of molecular targets for cancer diagnosis and therapy.
Abstract: Among the genes that were found to be abundantly overexpressed in highly metastatic rat cell lines compared to poorly metastatic cell lines, we identified a completely novel complementary DNA (cDNA) without any homologous or related genes in the database in 1994. The full-length cDNA of this rat gene was cloned, sequenced, and named metastasis-associated gene 1 (mta1), and eventually, its human cDNA counterpart, MTA1, was also cloned and sequenced by our group. MTA1 has now been identified as one of the members of a gene family (MTA gene family) and the products of the MTA genes, the MTA proteins, are transcriptional co-regulators that function in histone deacetylation and nucleosome remodeling and have been found in nuclear histone remodeling complexes. Furthermore, MTA1 along with its protein product MTA1 has been repeatedly and independently reported to be overexpressed in a vast range of human cancers and cancer cell lines compared to non-cancerous tissues and cell lines. The expression levels of MTA1 correlate well with the malignant properties of human cancers, strongly suggesting that MTA1 and possibly other MTA proteins (and their genes) could be a new class of molecular targets for cancer diagnosis and therapy.
24 citations
TL;DR: LRT formulations designed to improve mitochondrial function appear to be useful as non-toxic dietary supplements for reducing fatigue and restoring mitochondrial and other cellular membrane functions in patients with chronic illnesses and multiple chronic infections.
Abstract: Background: Many chronic diseases and illnesses are associated with one or more chronic infections, dysfunction of mitochondria and reduced production of ATP. This results in fatigue and other symptoms that occur in most if not all chronic conditions and diseases. Methods: This is a review of the published literature on chronic infections in neurodegenerative diseases and fatiguing illnesses that are also typified by mitochondrial dysfunction. This contribution also reviews the use of natural supplements to enhance mitochondrial function and reduce the effects of chronic infections to improve overall function in various chronic illnesses. Results: Mitochondrial function can be enhanced by the use of various natural supplements, notably Lipid Replacement Therapy (LRT) using glyerolphospholipids and other mitochondrial supplements. In various chronic illnesses that are characterized by the presence of chronic infections, such as intracellular bacteria ( Mycoplasma, Borrelia, Chlamydia and other infections) and viruses, LRT has proven useful in multiple clinical trials. For example, in clinical studies on chronic fatigue syndrome, fibromyalgia syndrome and other chronic fatiguing illnesses where a large majority of patients have chronic infections, LRT significantly reduced fatigue by 35-43% in different clinical trials and increased mitochondrial function. In clinical trials on patients with multiple intracellular bacterial infections and intractable fatigue LRT plus other mitochondrial supplements significantly decreased fatigue and improved mood and cognition. Conclusions: LRT formulations designed to improve mitochondrial function appear to be useful as non-toxic dietary supplements for reducing fatigue and restoring mitochondrial and other cellular membrane functions in patients with chronic illnesses and multiple chronic infections. Key words: Neurodegenerative and fatiguing illnesses, infections and mitochondrial dysfunction, ATP, Lipid Replacement Therapy (LRT)
11 citations
TL;DR: The researches for the identification and characterization of the mta1 gene, its human counterpart MTA1, and their protein products will be discussed.
Abstract: Metastasis is a complex series of sequential events involving several gene products and the regulated expression of several tumor cell genes. Using rat mammary adenocarcinoma cell lines of differing metastatic potentials and a differential complementary DNA (cDNA) hybridization method, our laboratory embarked in 1992 on a project to identify candidate metastasis-associated genes. Among the genes that were found to be abundantly overexpressed in highly metastatic rat cell lines compared to poorly metastatic cell lines, we identified a completely novel gene without any homologous or related genes in the database in 1994. The full-length cDNA of this gene was cloned, sequenced, and named mta1 (metastasis-associated gene 1), and eventually, its human cDNA counterpart, MTA1, was also cloned and sequenced by our group. MTA1 has now been identified as one of the members of a gene family (MTA gene family). The products of the MTA genes, the MTA proteins, are transcriptional co-regulators that function in histone deacetylation and nucleosome remodeling. In this review, we will briefly discuss the researches for the identification and characterization of the mta1 gene, its human counterpart MTA1, and their protein products.
10 citations
18 Sep 2014
TL;DR: This paper aims to demonstrate the efforts towards in-situ applicability of EMMARM, as to provide real-time information about the immune responses of mice to certain types of chemotherapy.
Abstract: 1 University of Medicine and Pharmacy “Carol Davila”, Department of Cellular and Molecular Medicine, 8, Eroilor Sanitari Blvd., 050474, Bucharest, Romania 2 “Victor Babes” National Institute of Pathology, 99101, Splaiul Independentei, 050096, Bucharest, Romania 3 University of Bucharest, Research Center for Applied Ethics, 204, Splaiul Independentei, 060024, Bucharest, Romania 4 Department of Molecular Pathology, Institute for Molecular Medicine, Huntington Beach, California, 92647 USA
3 citations